In the last trading session, 1.04 million Adverum Biotechnologies Inc (NASDAQ:ADVM) shares changed hands as the company’s beta touched 1.06. With the company’s per share price at $2.91 changed hands at -$0.06 or -2.02% during last session, the market valuation stood at $60.79M. ADVM’s last price was a discount, traded about -277.32% off its 52-week high of $10.98. The share price had its 52-week low at $2.71, which suggests the last value was 6.87% up since then. When we look at Adverum Biotechnologies Inc’s average trading volume, we note the 10-day average is 0.41 million shares, with the 3-month average coming to 197.38K.
Analysts gave the Adverum Biotechnologies Inc (ADVM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ADVM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Adverum Biotechnologies Inc’s EPS for the current quarter is expected to be -1.97.
Adverum Biotechnologies Inc (NASDAQ:ADVM) trade information
Instantly ADVM was in red as seen at the end of in last trading. With action -0.68%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -37.69%, with the 5-day performance at -0.68% in the red. However, in the 30-day time frame, Adverum Biotechnologies Inc (NASDAQ:ADVM) is -42.26% down. Looking at the short shares, we see there were 1.43 million shares sold at short interest cover period of 8.69 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 70.9% from its current market value. According to analyst projections, ADVM’s forecast low is 10 with 10 as the target high. To hit the forecast high, the stock’s price needs a -243.64% plunge from its current level, while the stock would need to soar -243.64% for it to hit the projected low.
Adverum Biotechnologies Inc (ADVM) estimates and forecasts
Year-over-year growth is forecast to reach -86.43% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.03%. The 2025 estimates are for Adverum Biotechnologies Inc earnings to increase by 16.09%, but the outlook for the next 5-year period is at 11.71% per year.
ADVM Dividends
Adverum Biotechnologies Inc is expected to release its next quarterly earnings report on 2025-Apr-14.
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.18% of Adverum Biotechnologies Inc shares while 77.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 89.36%. There are 77.59% institutions holding the Adverum Biotechnologies Inc stock share, with TCG CROSSOVER MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 12.1873% of the shares, roughly 2.01 million ADVM shares worth $13.78 million.
BML CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 9.4284% or 1.97 million shares worth $13.49 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 624.74 shares estimated at $1.82 million under it, the former controlled 2.99% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.81% of the shares, roughly 586.25 shares worth around $1.71 million.
